Correction, 18 September 2026: an earlier version of this post described April 7, 2026 as the end of the quarter. It is the date the results were reported.
What changed
$AEHR (Aehr Test Systems) reported results on April 7, 2026, and the headline numbers are rough. EPS swung from a profit of $0.07 a year earlier to a loss of -$0.05 — a full reversal from positive to negative territory. Revenue fell 43.7% year over year, a sharp contraction for a company that had been riding strong demand in its semiconductor test equipment niche.
The trailing P/E is currently 0, which reflects the absence of positive trailing earnings. The forward P/E stands at 9.9, suggesting the market is pricing in a recovery, though we do not have guidance commentary from management to anchor that expectation.
Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.
The ACCE score sits at 38/100. Breaking that down: Growth scores 7, Value 10, Quality 39, and Momentum 97. That Momentum score is striking given the underlying fundamentals — $AEHR has returned +380.2% over the past year, which explains the elevated momentum reading even as the business itself is contracting. The stock trades at $67.76 with a market cap of $2.28B, against an analyst consensus target of $71.33.
What it means
The Quality score of 39 and the sub-scores tell a consistent story. ROE is -8.7%, net margin is -25.2%, and FCF yield is -0.5%. The business is burning cash and not generating returns on equity right now. The one bright spot in the quality data is that earnings quality is flagged as strong, which suggests the reported losses are not being masked by accounting adjustments — the numbers reflect real operational pressure.
The disconnect between the Momentum score (97) and the Growth score (7) is the central tension in this stock. The share price has run hard over the past year, but the underlying business is shrinking revenue at a steep rate and has flipped to a net loss. Whether the forward P/E of 9.9 proves accurate depends entirely on a revenue recovery that the current quarter's data does not yet support.
We do not have guidance commentary to assess what management expects for the coming quarters. Until that picture clarifies, the ACCE score of 38 reflects a stock where price momentum has outrun fundamental improvement. For current price data and score updates, see acceinvestments.com/stocks/AEHR.
ACCE scores thousands of stocks across valuation models matched to each company, with fair value, conviction and the full thesis on every name. Start free, no card required.
